Abstract
30 patients with TS. aged 4.6-12.6 years were randomly allocated to receive oral ethinyl oestradiol (EE2) (0.5-2.0ug/day) or oxandrolone (OX) (0.625-1.25mg/day). Groups were matched for age, karyotype, pre-treatment height SDS for TS and height velocity SDS for TS (HV SDS) (Ranke).
HV SDS results (SD) after 0.5-1.0 yrs were as follows:
Response to EE2 was slightly less consistent than to OX (p < 0.05), with 2 non-responders.
Both treatments were well tolerated. Cliteromegaly was noted in 2 on OX; 3 on EE2 had early breast development.
24 hr growth hormone (GH) profiles were performed in 10 of each group before and during treatment. The sum of GH pulse amplitudes (SPA) was calculated using a computer algorithm (PULSAR). GH SPA was not changed by either treatment.
Used in appropriate dosage, both agents are safe, simple and effective agents in Turner syndrome. Neither appears to work via increased CH secretion.
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Massarano, A., Stanhope, R., Pringle, P. et al. 100 PROSPECTIVE RANDOMISED STUDY OF LOW DOSE ETHINYL-OESTRADIOL AND OXANDROLONE IN TURNER SYNDROME (TS). Pediatr Res 24, 533 (1988). https://doi.org/10.1203/00006450-198810000-00121
Issue Date:
DOI: https://doi.org/10.1203/00006450-198810000-00121